Pharma channel feed

Am­i­cus CEO Crow­ley bags a gene ther­a­py com­pa­ny, a new pipeline — and a great pho­to op — for $100M in cash

7 years ago
Cell/Gene Tx

Take­da bless­es a lit­tle biotech's en­gi­neered tox­in tech for mul­ti­ple myelo­ma, trig­ger­ing a bases loaded home run

7 years ago

Cal­i­for­nia in­sur­ance com­mis­sion­er files suit against Ab­b­Vie, claims wide­spread kick­back scheme to pro­mote its block­buster Hu­mi­ra

7 years ago

Unit­ed’s Mar­tine Roth­blatt en­dors­es a biotech uni­corn’s CEO and antes up for US rights to an IPF drug

7 years ago
R&D

Servi­er shrugs off a mul­ti­mil­lion-dol­lar in­vest­ment, aban­don­ing a failed MS drug de­vel­oped by GeNeu­ro

7 years ago
R&D

An­oth­er sci­en­tist pleads guilty for his role in a scheme to sell GSK's trade se­crets in Chi­na

7 years ago
People
China

No­vo Nordisk is whack­ing 400 R&D jobs, re­or­ga­niz­ing glob­al R&D ops around 4 “trans­for­ma­tion­al” units

7 years ago
R&D

Law­mak­ers halt push for drug prices in TV ads

7 years ago

Sen­si­tized by a se­ries of scan­dals around the world, No­var­tis spot­lights its ethics poli­cies

7 years ago

Launch a new com­pa­ny, steer a $150M IPO and ink a big da­ta col­lab­o­ra­tion — they call it Mon­day at Vivek Ra­maswamy’s Roivant

7 years ago
Financing
Startups

Can­cer Re­search UK launch­es new Lon­don Cen­tre, in­fus­ing £14M in­to bio­ther­a­peu­tics work from lead­ing in­sti­tutes

7 years ago
R&D

CRISPR pays to part­ner with Vi­a­Cyte on an off-the-shelf gene-edit­ing ap­proach to cur­ing di­a­betes

7 years ago

The FDA lifts a par­tial hold on Mer­sana's top drug -- and then its shares crater

7 years ago

An­timi­cro­bial re­sis­tance: FDA dis­cuss­es re­im­burse­ment re­forms

7 years ago

Te­va gets a bad­ly need­ed win: FDA OKs their run­ner-up CGRP mi­graine drug, with Eli Lil­ly trail­ing be­hind

7 years ago

Re­gen­eron maps a dra­mat­ic ex­pan­sion with 1,500 new jobs — and that makes NY’s gov­er­nor very hap­py

7 years ago

The lat­est tem­pest over a dra­mat­ic drug price hike riles two pow­er­ful sen­a­tors — who can't ac­tu­al­ly do any­thing about it

7 years ago

As­traZeneca grabs an FDA OK for its new leukemia drug, to be mar­ket­ed as Lu­mox­i­ti

7 years ago

Phar­ma com­pa­nies out­per­form in­sti­tu­tions in Eu­ro­pean clin­i­cal tri­al re­port­ing amid prob­lem­at­ic over­all trends — Ox­ford study

7 years ago

SEC charges that hedge fund man­ag­er (and priest) re­lied on false claims to pro­mote a Lig­and short at­tack

7 years ago
People

BIO, Al­ler­gan and Roche call for FDA flex­i­bil­i­ty with pa­tient ex­pe­ri­ence da­ta

7 years ago

Skirt­ing a group of pi­o­neers, Gilead part­ners with gene-edit­ing up­start Pre­ci­sion Bio in hunt to cure hep B

7 years ago

A Mar­tin Shkre­li wannabe de­fends a big spike in drug price and earns a Twit­ter lash­ing from the FDA's com­mish

7 years ago

Mer­ck her­alds a rare Big Phar­ma suc­cess for an­tibi­ot­ic PhI­II, but it’s al­so a cau­tion­ary tale about the mar­ket

7 years ago
R&D
First page Previous page 291292293294295296297 Next page Last page
A service from the Financial Times